Elabscience

Recombinant Human Urokinase/uPA Protein (His Tag)(Active)

Product Code:
 
PKSH031415
Product Group:
 
Recombinant Proteins
Supplier:
 
Elabscience
Host Type:
 
Human
Regulatory Status:
 
RUO
Application:
 
Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
 
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
 
Generally lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
PKSH031415-20ug20ug£467.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: China.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Abbreviation:
Urokinase;uPA
Accession:
NP_002649.1
Activity:
Immobilized human uPA at 5 ug/ml (100 ul/well) can bind mouse PLAUR with a linear ranger of 1. 6-40 ng/ml.
Background:
Plasminogen activator, urokinase, also known as PLAU and uPA, is a serine protease which converts plasminogen to plasmin, a broad-spectrum protease active on extracellular matrix (ECM) components. It is involved in complement activation, cell migration, wound healing, and generation of localized extracellular proteolysis during tissue remodelling, pro-hormone conversion, carcinogenesis and neoplasia. uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction). The role of uPA is not only linked to its action as an enzyme. In fact, the mere binding of uPA on the cell surface also brings about two events that broaden the spectrum of its biological functions: (1) a conformational change of the receptor, which, in turn, affects its interaction with other proteins, (2) a signal transduction which modulates the expression of apoptosis-related genes. Besides its applications as a thrombolytic agent and as a prognostic marker for tumors, uPA may provide the basis for other therapies, as the structure of the receptor-binding domain of uPA has become a model for the design of anti-cancer molecules. Because of the causal involvment of uPA in cancer invasion and metastasis, the blockade of uPA interactions and activity with specific inhibitors is of interest for novel strategies in cancer therapy.
Calculated MW:
46 kDa
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
HEK293 Cells
Formulation:
Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
C-His
ObservedMW:
18, 32 and 50 kDa
Purity:
> 97 % as determined by reducing SDS-PAGE.
Sequence:
Met 1-Leu 431
Target Synonym:
Urokinase-Type Plasminogen Activator;U-Plasminogen Activator;uPA;PLAU;ATF;BDPLT5;QPD;u-PA;UPA;URK

Documents